A diverse, summer issue with articles on topics ranging from content marketing to the role of experience in a VUCA world. Also, the latest book for Medical Reps reviewed by Prof. Vivek Hattangadi

Articles by Vivek Hattangadi, Genesh Kuriakose, Pankaj Mehrotra, Salil Kallianpur and Jay Mehta

Articles by K. Hariram, Vivek Hattangadi, Soham Wagh, Dr. Rajshri Jobanputra, and Rashesh Patel

When was the first time that we heard the...

To be able to measure the RoI on digital in pharma, it is necessary to understand customers as individuals and create newer segmentation based on these needs and interests. This calls for the NextGen RCPA of data collection and personalized communications that engage customers, based on which pharma must create customer experiences that matter to them. If your content does not scratch, where it itches the customers, digital or phygital, customers will not feel at home (comfortable, delighted, and wants more), which is what matters. Not a digital euphoria, which will soon die down as customers simply ignore it as they did when pharma launched a plethora of webinars.

India’s caesarean section debate is drifting toward polarisation. On one...

In big pharma, leadership changes are rarely impulsive. They...

How a niche Indian topicals manufacturer outgrew its CDMO...

Transparency, Trust, and the Problem of “Invisible Evidence” in...

India’s pharmaceutical industry occupies a unique and powerful position...

India’s caesarean section debate is drifting toward polarisation. On one...

In big pharma, leadership changes are rarely impulsive. They...

How a niche Indian topicals manufacturer outgrew its CDMO...

Transparency, Trust, and the Problem of “Invisible Evidence” in...

India’s pharmaceutical industry occupies a unique and powerful position...

India’s caesarean section debate is drifting toward polarisation. On one...

In big pharma, leadership changes are rarely impulsive. They...

How a niche Indian topicals manufacturer outgrew its CDMO...

Transparency, Trust, and the Problem of “Invisible Evidence” in...

India’s pharmaceutical industry occupies a unique and powerful position...

India’s caesarean section debate is drifting toward polarisation. On one...

In big pharma, leadership changes are rarely impulsive. They...

How a niche Indian topicals manufacturer outgrew its CDMO...

Transparency, Trust, and the Problem of “Invisible Evidence” in...

India’s pharmaceutical industry occupies a unique and powerful position...